2 Information about brentuximab vedotin
|
Marketing authorisation indication |
Brentuximab vedotin is indicated for the treatment of 'adult patients with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy'. |
|---|---|
|
Dosage in the marketing authorisation |
The recommended dose is 1.8 mg/kg given as an intravenous infusion over 30 minutes every 3 weeks. People with CTCL should have up to 16 cycles. |
|
Price |
The price of brentuximab vedotin is £2,500 for a 50 mg vial (excluding VAT; BNF edition 76). The company has a commercial arrangement. This makes brentuximab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount. |